- Home
- TCRT vs CYCN Comparison
TCRT vs CYCN Comparison
Compare TCRT & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRT | CYCN |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TCRT | CYCN |
|---|---|---|
| Price | $2.61 | $1.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.3K | ★ 3.9M |
| Earning Date | 11-14-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $6,000.00 | ★ $2,855,000.00 |
| Revenue This Year | $5,680,500.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1371.65 |
| 52 Week Low | $1.31 | $1.16 |
| 52 Week High | $6.20 | $6.25 |
Technical Indicators
Market Signals| Indicator | TCRT | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 39.66 |
| Support Level | $2.60 | $1.33 |
| Resistance Level | $3.02 | $1.52 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 10.43 | 2.33 |
Price Performance
Historical ComparisonAbout TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.